B
BVF Partners L.P.
+ HältXFOR
-6.96%
3-Monats-Rendite
$3.240
+0.072 (+2.21%)Zum Schluss
Loading chart…
- Hoch
- 3.360
- Eröffnung
- 3.300
- Volumengewichteter Durchschnittskurs
- 3.23
- Volumen
- 536.59K
- Marktkap.
- 112.54M
- Tief
- 3.100
- Umsatz
- 1.73M
- EV/EBITDA, TTM
- -9.90
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
KI-Analyse of X4 Pharmaceuticals Inc (XFOR)
KaufenX4 Pharmaceuticals Inc is a good buy right now due to its recent positive earnings report showing a revenue increase of 347.2% year-over-year, with a current price of $3.35 significantly below the analyst target of $12. Additionally, the RSI is at 78.67, indicating strong momentum. The main risk is the upcoming earnings report, with an estimated EPS of -0.19, which could impact investor sentiment.
Bewertungskennzahlen
Das aktuelle erwartete KGV von X4 Pharmaceuticals Inc (XFOR) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -1.85.
Whales, die XFOR halten
Event-Zeitleiste
News
1.011-03NewsfilterX4 Pharmaceuticals to Participate in Multiple Investment Conferences
- 2.010-29Newsfilter
X4 Pharmaceuticals Highlights Market Opportunity and Clinical Progress for Mavorixafor
9.009-08NASDAQ.COMX4 Pharmaceuticals Achieves Positive FDA Meeting Outcome
- 9.009-08Newsfilter
FDA Approves Reduced Sample Size for 4WARD Trial
- 5.009-01Newsfilter
X4 Pharmaceuticals Grants Stock Options to New Employees
XFOR FAQ – beantwortet von Alphio AI
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
X4 Pharmaceuticals Inc is a good buy right now due to its recent positive earnings report showing a revenue increase of 347.2% year-over-year, with a current price of $3.35 significantly below the analyst target of $12. Additionally, the RSI is at 78.67, indicating strong momentum. The main risk is the upcoming earnings report, with an estimated EPS of -0.19, which could impact investor sentiment.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
- AppLovin Q3 2026 Deep Dive: Beaten-Down S&P Dog Meets Axon Next-Gen Beat-and-Raise—and a $3.2B BuybaAppLovin Q3 2026: $2.185B rev (+55%), EPS $4.30 vs ~$4.03–4.04 Street, Adj EBITDA $1.842B (84%). Beat own guide $100M; Q4 $2.365–2.395B; auth +$3.2B; AH +22–24%.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.